Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + CAR T-Cell Therapy in Aggressive B-Cell NHL
NCT05202782Phase 2Active, not recruiting
- Sponsor
- Northwestern University
- Start
- Mar 2022
- Primary completion
- Oct 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in B-cell non-Hodgkin lymphoma and transformed indolent B-cell lymphoma, sponsored by Northwestern University. Primary endpoint: Change in 6-month complete response rates. Started Mar 2022; status: active, not recruiting.
02
Drugs
zanubrutinib
03
Conditions
B-cell non-Hodgkin lymphomatransformed indolent B-cell lymphoma
Beyond the preview
Go deeper on NCT05202782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05202782.